Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The lower the better in cholesterol

By Mindo - 08th Nov 2021 | 64 views

Healthy food in heart and water diet sport lifestyle concept

Irish Cardiac Society 72nd Annual Scientific Meeting and AGM, virtual, 7-9 October 2021

The ICS 72nd Annual Scientific Meeting and AGM heard from keynote speaker Prof Kausik K Ray of Imperial College London, who addressed the meeting on the topic, ‘ASCVD [atherosclerotic cardiovascular disease] Prevention: Unmet
needs and the promise of population health through siRNA-based therapies’.

“I think we are at a really exciting time, because you can only start to fix problems when you look at the issues. Some of these may be clinical in terms of how we find patients, healthcare systems, and also in terms of patients’ behaviours and their health literacy,” said Prof Ray. “It doesn’t matter where you are in the world, we have a more or less global approach in terms of lipid-lowering and prevention.

We don’t want to over-treat low-risk people, but we don’t want to under-treat high-risk individuals,” said Prof Ray. Many guidelines suggest what to do at a population level, but when it comes to data from cholesterol treatment trials, “the third iteration is really my favourite because it really shows you the two basic determinants of absolute benefits from lipid-lowering,” he told the attendees. Prof Ray presented data from guidelines and told the meeting: “The first thing to point out is, there is no such thing as a ‘normal’ LDL.

The more you lower LDL cholesterol, the more benefit you get, and the amount of benefit you get really depends on the baseline risk.” He explained that if there is an annualised risk of less than one per cent, “lower is clearly better. But if I am trying to implement a really aggressive approach in everybody who is at low risk, the more you lower LDL cholesterol, the more benefit you get, and the amount of benefit you get really depends on the baseline risk.” Prof Ray presented an overview of the European Society of Cardiology/European Atherosclerosis Society risk-based LDL-C goals and broke patients down according to their risk categories and recommended LDL-C goals.

“What we can see is that as the risk increases, the cholesterol goals become lower and lower,” he pointed out. As the LDL-C goals have become lower in recent years, the challenge for physicians is how to achieve those goals with existing therapies, he said. Prof Ray outlined data from the DA VINCI study and noted that “the aim is to get patients to control [cholesterol levels], irrespective of whether you are using one, two or three drugs”. He emphasised the importance of the study in changing thinking about cholesterol and said,“the message is simple – in Europe, between
those two sets of guidelines, what we were practising was essentially statin-based monotherapy… the key thing to note about combination therapies is that it [level] was really low.

“With a statin-based monotherapy approach to our patients, in primary or secondary prevention, the risk-based goal attainment would only be effective in about 50 per cent of patients. As soon as we reset those goals to reflect
the data and what we now have available, that’s going to fall to one-in-three. So we have to get it into our heads that we will have to use more combination therapy.”

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read